In the latest session, MaxCyte Inc (NASDAQ: MXCT) closed at $4.46 up 6.95% from its previous closing price of $4.17. In other words, the price has increased by $+0.2900 from its previous closing price. On the day, 772616 shares were traded.
Ratios:
For a deeper understanding of MaxCyte Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 9.97 and its Current Ratio is at 10.65. In the meantime, Its Debt-to-Equity ratio is 0.08 whereas as Long-Term Debt/Eq ratio is at 0.08.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Craig Hallum on November 29, 2023, initiated with a Buy rating and assigned the stock a target price of $7.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Jan 26 ’24 when Johnston John Joseph sold 5,000 shares for $5.12 per share. The transaction valued at 25,585 led to the insider holds 120,583 shares of the business.
Johnston John Joseph sold 5,000 shares of MXCT for $22,650 on Dec 26 ’23. The Director now owns 120,583 shares after completing the transaction at $4.53 per share. On Dec 05 ’23, another insider, Doerfler Douglas, who serves as the President and CEO of the company, sold 99,442 shares for $5.17 each. As a result, the insider received 514,115 and left with 333,197 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MXCT now has a Market Capitalization of 434.13M and an Enterprise Value of 284.59M. For the stock, the TTM Price-to-Sale (P/S) ratio is 11.25 while its Price-to-Book (P/B) ratio in mrq is 2.00. Its current Enterprise Value per Revenue stands at 6.89 whereas that against EBITDA is -6.45.
Stock Price History:
Over the past 52 weeks, MXCT has reached a high of $5.55, while it has fallen to a 52-week low of $2.45. The 50-Day Moving Average of the stock is 4.7421, while the 200-Day Moving Average is calculated to be 4.2353.
Shares Statistics:
For the past three months, MXCT has traded an average of 704.16K shares per day and 841.78k over the past ten days. A total of 103.96M shares are outstanding, with a floating share count of 91.47M. Insiders hold about 12.16% of the company’s shares, while institutions hold 70.28% stake in the company. Shares short for MXCT as of Feb 29, 2024 were 3.1M with a Short Ratio of 4.41, compared to 3.12M on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 3.00% and a Short% of Float of 3.04%.
Earnings Estimates
There are 6 different market analysts currently analyzing its stock. On average, analysts expect EPS of -$0.13 for the current quarter, with a high estimate of -$0.12 and a low estimate of -$0.15, while EPS last year was -$0.11. The consensus estimate for the next quarter is -$0.13, with high estimates of -$0.12 and low estimates of -$0.15.
Analysts are recommending an EPS of between -$0.4 and -$0.59 for the fiscal current year, implying an average EPS of -$0.48. EPS for the following year is -$0.42, with 7 analysts recommending between -$0.29 and -$0.54.
Revenue Estimates
A total of 6 analysts believe the company’s revenue will be $7.48M this quarter.It ranges from a high estimate of $7.91M to a low estimate of $6.2M. As of the current estimate, MaxCyte Inc’s year-ago sales were $8.58M, an estimated decrease of -12.80% from the year-ago figure. For the next quarter, 6 analysts are estimating revenue of $8.1M, a decrease of -10.40% over than the figure of -$12.80% in the same quarter last year. There is a high estimate of $8.5M for the next quarter, whereas the lowest estimate is $7.5M.
A total of 7 analysts have provided revenue estimates for MXCT’s current fiscal year. The highest revenue estimate was $38.9M, while the lowest revenue estimate was $33M, resulting in an average revenue estimate of $34.54M. In the same quarter a year ago, actual revenue was $41.29M, down -16.30% from the average estimate. Based on 7 analysts’ estimates, the company’s revenue will be $46.69M in the next fiscal year. The high estimate is $56.7M and the low estimate is $40.6M. The average revenue growth estimate for next year is up 35.20% from the average revenue estimate for this year.
